A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
- Registration Number
- NCT01435629
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 81
Inclusion Criteria
- Patients who were enrolled in the GH-1941 study (1997 to 2006) and expected to theoretically reach the adult height within the study period
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Norditropin® somatropin -
- Primary Outcome Measures
Name Time Method To collect change data of adult height (cm) of patients treated with Norditropin® and evaluate the long-term efficacy At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age
- Secondary Outcome Measures
Name Time Method To monitor the patients to see if they undergo lower limb lengthening At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇯🇵Tokyo, Japan